Application of CRISPR/Cas9 Genome Editing to Improve Recombinant Protein Production in CHO Cells
- 11 May 2017
- book chapter
- Published by Springer Nature
- Vol. 1603, 101-118
Abstract
Genome editing has become an increasingly important aspect of Chinese Hamster Ovary (CHO) cell line engineering for improving production of recombinant protein therapeutics. Currently, the focus is directed toward expanding the product diversity, controlling and improving product quality and yields. In this chapter, we present our protocol on how to use the genome editing tool Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)/CRISPR-associated protein 9 (Cas9) to knockout engineering target genes in CHO cells. As an example, we refer to the glutamine synthetase (GS)-encoding gene as the knockout target gene, a knockout that increases the selection efficiency of the GS-mediated gene amplification system.Keywords
This publication has 10 references indexed in Scilit:
- The art of CHO cell engineering: A comprehensive retrospect and future perspectivesBiotechnology Advances, 2015
- CRISPR/Cas9‐mediated genome engineering of CHO cell factories: Application and perspectivesBiotechnology Journal, 2015
- One‐step generation of triple knockout CHO cell lines using CRISPR/Cas9 and fluorescent enrichmentBiotechnology Journal, 2015
- Accelerating genome editing in CHO cells using CRISPR Cas9 and CRISPy, a web‐based target finding toolBiotechnology and Bioengineering, 2014
- A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial ImmunityScience, 2012
- Improving the efficiency of CHO cell line generation using glutamine synthetase gene knockout cellsBiotechnology and Bioengineering, 2011
- The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNANature, 2010
- Culture of Animal Cells2010
- Limitations to the Development of Humanized Antibody Producing Chinese Hamster Ovary Cells Using Glutamine Synthetase-Mediated Gene AmplificationBiotechnology Progress, 2006
- Production of recombinant protein therapeutics in cultivated mammalian cellsNature Biotechnology, 2004